▎Armstrong2025年12月16日,葛兰素史克在Clinicaltrials.gov网站上注册了B7H4 ADC新药GSK5733584治疗子宫内膜癌、卵巢癌的全球三期临床试验,分别计划入组600例、450例受试者。GSK5733584即葛兰素史克从翰森制药引进的HS-20089。翰森制药B7H4 ADC新药HS-20089的通用名为Mocertatug rezetecan。HS-...
Source Link▎Armstrong2025年12月16日,葛兰素史克在Clinicaltrials.gov网站上注册了B7H4 ADC新药GSK5733584治疗子宫内膜癌、卵巢癌的全球三期临床试验,分别计划入组600例、450例受试者。GSK5733584即葛兰素史克从翰森制药引进的HS-20089。翰森制药B7H4 ADC新药HS-20089的通用名为Mocertatug rezetecan。HS-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.